Science Explorer Back to mapMap

Most cited papers from Melanoma Institute Australia

What are the most cited papers from Melanoma Institute Australia?

The most cited paper from Melanoma Institute Australia is "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma" (James Larkin et al., 2015), with 8,266 citations. Next come "Pembrolizumab versus Ipilimumab in Advanced Melanoma" (5,968) and "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma" (5,453).

Showing 50 of 60 papers. Every paper with more than 717 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin et al. · New England Journal of Medicine Open access 31 May 2015 8,266
2 Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert et al. · New England Journal of Medicine Open access 19 Apr 2015 5,968
3 Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Jedd D. Wolchok et al. · New England Journal of Medicine Open access 11 Sep 2017 5,453
4 Nivolumab in Previously Untreated Melanoma without BRAF Mutation Caroline Robert et al. · New England Journal of Medicine Open access 16 Nov 2014 5,431
5 The repertoire of mutational signatures in human cancer Ludmil B. Alexandrov et al. · Nature Open access1,384 authors 5 Feb 2020 3,854
6 Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma James Larkin et al. · New England Journal of Medicine Open access 28 Sep 2019 3,784
7 Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid et al. · New England Journal of Medicine Open access 2 Jun 2013 3,425
8 Pan-cancer analysis of whole genomes Lauri A. Aaltonen et al. · Nature Open access1,324 authors 5 Feb 2020 3,360
9 Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Keith T. Flaherty et al. · New England Journal of Medicine Open access 30 Sep 2012 2,838
10 Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Caroline Robert et al. · New England Journal of Medicine Open access 16 Nov 2014 2,718
11 Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors Daniel Y. Wang et al. · JAMA Oncology Open access 18 Sep 2018 2,692
12 Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System Charles M. Balch, Seng‐Jaw Soong, Jeffrey E. Gershenwald et al. · Journal of Clinical Oncology 15 Aug 2001 2,418
13 Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual Jeffrey E. Gershenwald, Richard A. Scolyer, Kenneth R. Hess et al. · CA A Cancer Journal for Clinicians Open access 13 Oct 2017 2,317
14 Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Jeffrey S. Weber et al. · New England Journal of Medicine Open access 10 Sep 2017 2,249
15 Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. Elizabeth Ann Grimm, A Mazumder, H Z Zhang et al. · The Journal of Experimental Medicine Open access Jun 1982 2,216
16 Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib Jeffrey Alan Sosman et al. · New England Journal of Medicine Open access 22 Feb 2012 2,170
17 Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Alexander M.M. Eggermont et al. · New England Journal of Medicine Open access 15 Apr 2018 1,906
18 Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Caroline Robert et al. · The Lancet 14 Jul 2014 1,779
19 Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Antoni Ribas et al. · The Lancet Oncology Open access 24 Jun 2015 1,581
20 Whole-genome landscapes of major melanoma subtypes Nicholas K. Hayward et al. · Nature Open access May 2017 1,548
21 Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy Antoni Ribas, Reinhard Dummer, Igor J. Puzanov et al. · Cell Open access Sep 2017 1,523
22 Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040 Melina Arnold, Deependra Singh, Mathieu Laversanne et al. · JAMA Dermatology Open access 30 Mar 2022 1,520
23 Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma Georgina Venetia Long et al. · New England Journal of Medicine Open access 10 Sep 2017 1,501
24 Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma Donald L. Morton, John F. Thompson, Alistair J. Cochran et al. · New England Journal of Medicine Open access 12 Feb 2014 1,490
25 Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Georgina Venetia Long et al. · The Lancet 31 May 2015 1,419
26 Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma Mark B. Faries et al. · New England Journal of Medicine Open access 7 Jun 2017 1,415
27 Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Caroline Robert et al. · New England Journal of Medicine Open access 4 Jun 2019 1,412
28 Targeted agents and immunotherapies: optimizing outcomes in melanoma Jason J. Luke, Keith T. Flaherty, Antoni Ribas et al. · Nature Reviews Clinical Oncology Review 4 Apr 2017 1,316
29 Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Jacob Schachter, Antoni Ribas, Georgina Venetia Long et al. · The Lancet 16 Aug 2017 1,256
30 Immune checkpoint inhibitors in melanoma Matteo Salvatore Carlino, James Larkin, Georgina Venetia Long · The Lancet Sep 2021 1,231
31 Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Caroline Robert, Antoni Ribas, Jacob Schachter et al. · The Lancet Oncology Open access 22 Jul 2019 1,179
32 The evolutionary history of 2,658 cancers Moritz Gerstung et al. · Nature Open access1,441 authors 5 Feb 2020 1,149
33 Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma Jedd D. Wolchok et al. · Journal of Clinical Oncology Open access 24 Nov 2021 1,144
34 Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy Tuba Nur Gide et al. · Cancer Cell Open access Feb 2019 1,086
35 Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Antoni Ribas et al. · JAMA Open access 19 Apr 2016 1,081
36 Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer Jeanne Tie et al. · New England Journal of Medicine Open access 4 Jun 2022 1,076
37 An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer Katherine Stemke‐Hale et al. · Cancer Research Open access Aug 2008 1,054
38 Patterns of somatic structural variation in human cancer genomes Yilong Li et al. · Nature Open access1,411 authors 5 Feb 2020 1,005
39 Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study Georgina Venetia Long, Victoria G. Atkinson, Serigne Lo et al. · The Lancet Oncology 27 Mar 2018 1,005
40 Caveolae: From Cell Biology to Animal Physiology Babak Razani, Scott Eric Woodman, Michael P. Lisanti · Pharmacological Reviews Sep 2002 994
41 Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study Georgina Venetia Long, Reinhard Dummer, Omid Hamid et al. · The Lancet Oncology 17 Jun 2019 991
42 Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Omid Hamid, Caroline Robert, ADIL I. DAUD et al. · Annals of Oncology Open access 29 Jan 2019 961
43 Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Gerald Steven Falchook, Georgina Venetia Long, Razelle Kurzrock et al. · The Lancet Open access May 2012 946
44 Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial Georgina Venetia Long et al. · The Lancet Oncology 7 Oct 2012 920
45 β-Cell death during progression to diabetes Diane J. Mathis, Luis Vence, Christophe O. Benoist · Nature Dec 2001 887
46 Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study Jeffrey S. Weber et al. · The Lancet 21 Jan 2024 871
47 Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting M. Vestergaard, Petra Macaskill, Phoebe E Holt et al. · British Journal of Dermatology Review Jun 2008 867
48 Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab Alexander Maxwell Menzies, Douglas Buckner Johnson, Sangeetha Ramanujam et al. · Annals of Oncology Open access 29 Sep 2016 831
49 Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Imran G. House, Peter Savas, Junyun Lai et al. · Clinical Cancer Research 21 Oct 2019 815
50 Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma Christine Guo Lian et al. · Cell Open access Sep 2012 813

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.